RT3 — Peptide Dosing Protocols reference

patient_educationexpert_opinion · status: needs_provider_review

Details

Author: —

Citation: —

Summary (generated — provider review required)

Retatrutide Dosing Guide: 1-12 mg Weekly Triple Agonist (2026) Shop Protocols Stacks A–Z Index Email Updates Home Protocols Retatrutide Protocol Guide - Dosing, Reconstitution & Safety Protocol / Research Dosing Guide Retatrutide Protocol Guide - Dosing, Reconstitution & Safety Step-by-step retatrutide research dosing reference: 1-12 mg once-weekly titration, full reconstitution chart, supplies-by-cycle math, Phase 3 results, and the dysesthesia safety signal. By Garret Grant · Founder & Lead Researcher · Last reviewed June 2026 · Share Supplier Pick Copy code PEPPAL Copy code PEPPAL Verified Supplier Verified Supplier Peptide Partners Retatrutide (GLP-3) Supply View Retatrutide Table of Contents View Supplies Quick Start Dosing Protocol & Schedule Supplies Needed Reconstitution Guide Dosage Chart Mechanism Who Should Avoid It Side Effects & Safety Timeline & Monitoring Clinical Evidence Storage & Handling Troubleshooting Regulatory Status Retatrutide Comparisons Related Protocols Blood Tests FAQ References Retatrutide Quick Start Retatrutide is a research peptide being studied as a once-weekly shot for weight and metabolic outcomes. Researchers care about it because it acts on three hormone pathways at once: GLP-1, GIP, and glucagon.

The original source document remains the source of truth. Generated summaries are not authoritative.

Linked assets (5) · phenotypes (1)

evidence_reference, dosing_reference, mechanism, safety_reference, monitoring_reference

Phenotypes: metabolic_dysfunction

Findings (208) · awaiting review (158)

safety · pending

GI side effects (nausea) may begin.

dosing · pending

By Garret Grant · Founder & Lead Researcher · Last reviewed June 2026 · Share Supplier Pick Copy code PEPPAL Copy code PEPPAL Verified Supplier Verified Supplier Peptide Partners Retatrutide (GLP-3) Supply View Retatrutide Table of Contents View Supplies Quick Start Dosing Protocol & Schedule Supplies Needed Reconstitution Guide Dosage Chart Mechanism Who Should Avoid It Side Effects & Safety Timeline & Monitoring Clinical Evidence Storage & Handling Troubleshooting Regulatory Status Retatrutide Comparisons Related Protocols Blood Tests FAQ References Retatrutide Quick Start Retatrutide is a research peptide being studied as a once-weekly shot for weight and metabolic outcomes.

mechanism · pending

Researchers care about it because it acts on three hormone pathways at once: GLP-1, GIP, and glucagon.

dosing · pending

This page covers the typical research-protocol structure: the 1 mg start, the slow

dosing · pending

titration up to 12 mg, how to reconstitute the vial, how to plan supplies, and what the Phase 2 and Phase 3 trial data show.

dosing · pending

Route Subcutaneous injection, once per week, on the same day each week.

dosing · pending

Schedule Climb every 4 weeks: 1 mg - 2 mg - 4 mg - 6 mg - 9 mg - 12 mg.

dosing · pending

Measure U-100 insulin syringes; vial size and BAC water volume set how many units equal each dose.

regulatory · pending

Research status Investigational; not FDA-approved as of June 2026.

dosing · pending

This page is for dose steps, titration, vial mixing, and supplies.

safety · pending

It covers how it works, trial data, side effects, and legal status.

dosing · pending

Retatrutide Dosing Protocol & Schedule The retatrutide dosing protocol is built as a slow climb, not a dose to jump into.

dosing · pending

The starting dose in clinical trials is 1 mg once weekly.

dosing · pending

The titration schedule then steps up every 4 weeks so the body can adjust before higher doses are reached.

dosing · pending

Phase 2 (NEJM, 2023) used 1 - 2 - 4 - 8 - 12 mg with no 6 mg step.

dosing · pending

ntermediate 6 mg step and treats 4 mg, 9 mg, and 12 mg as target maintenance doses depending on the trial arm.

dosing · pending

Phase 3 TRIUMPH titration (current standard) Phase 3 TRIUMPH retatrutide titration schedule Phase Initiation Weeks Weeks 1-4 Weekly Dose 1 mg Notes Starting dose.

dosing · pending

Phase Early escalation Weeks Weeks 5-8 Weekly Dose 2 mg Notes First step up.

dosing · pending

Phase Mid escalation Weeks Weeks 9-12 Weekly Dose 4 mg Notes Appetite suppression usually becomes noticeable.

dosing · pending

Phase High escalation Weeks Weeks 13-16 Weekly Dose 6 mg Notes Phase 3 added this intermediate step.

dosing · pending

Peptide Vials (10 mg vials) 10 mg vial is the most common research format.

dosing · pending

Phase Therapeutic range Weeks Weeks 17-20 Weekly Dose 9 mg Notes Phase 3 target dose for many TRIUMPH arms.

dosing · pending

Phase Maximum studied Weeks Weeks 21+ Weekly Dose 12 mg Notes Maximum dose studied.

dosing · pending

Phase Weeks Weekly Dose Notes Initiation Weeks 1-4 1 mg Starting dose.

dosing · pending

Early escalation Weeks 5-8 2 mg First step up.

dosing · pending

Mid escalation Weeks 9-12 4 mg Appetite suppression usually becomes noticeable.

dosing · pending

High escalation Weeks 13-16 6 mg Phase 3 added this intermediate

dosing · pending

Phase 2 jumped from 4 mg straight to 8 mg.

dosing · pending

Therapeutic range Weeks 17-20 9 mg Phase 3 target dose for many TRIUMPH arms.

dosing · pending

Maximum studied Weeks 21+ 12 mg Maximum dose studied.

dosing · pending

Phase 2 NEJM titration (still common in research) Phase 2 retatrutide titration schedule Phase Initiation Weeks Weeks 1-4 Weekly Dose 1 mg Phase Early escalation Weeks Weeks 5-8 Weekly Dose 2 mg Phase Mid escalation Weeks Weeks 9-12 Weekly Dose 4 mg Phase High escalation Weeks Weeks 13-16 Weekly Dose 8 mg Phase Maximum Weeks Weeks 17+ Weekly Dose 12 mg Phase Weeks Weekly Dose Initiation Weeks 1-4 1 mg Early escalation Weeks 5-8 2 mg Mid escalation Weeks 9-12 4 mg High escalation Weeks 13-16 8 mg Maximum Weeks 17+ 12 mg Source: Jastreboff et al., NEJM 2023.

dosing · pending

Cycle guidelines Cycle guidelines Approach Phase 2 reference Duration 48 weeks Review Point Every 4 weeks at each dose step Best For Matches the original NEJM trial structure Approach Phase 3 TRIUMPH reference Duration 68-72 weeks Review Point Every 4 weeks; review at 4 mg, 9 mg, 12 mg Best For Mirrors current Phase 3 maintenance arms Approach Slow titration Duration Add 2-4 weeks per dose step when GI symptoms persist Review

dosing · pending

24 weeks 6 vials Through 12 mg first month = 136 mg total.

dosing · pending

8 weeks 1 vial Through Week 8 = 12 mg total; one 24 mg vial covers it with margin.

dosing · pending

Point Each dose step Best For When nausea, vomiting, or diarrhea is hard to tolerate Approach Duration Review Point Best For Phase 2 reference 48 weeks Every 4 weeks at each dose step Matches the original NEJM trial structure Phase 3 TRIUMPH reference 68-72 weeks Every 4 weeks; review at 4 mg, 9 mg, 12 mg Mirrors current Phase 3 maintenance arms Slow titration Add 2-4 weeks per dose step when GI symptoms persist Each dose step When nausea, vomiting, or diarrhea is hard to tolerate Trial protocols allowed participants to stay at the current dose for an extra 2-4 weeks when GI side effects were significant.

dosing · pending

Titration pacing matters In the Phase 2 NEJM trial, GI side effect rates nearly doubled when participants jumped to 8 mg instead of climbing gradually from 1-2 mg.

dosing · pending

Slower titration was the main lever for adherence.

dosing · pending

This is not a dosing recommendation - it is a math tool.

dosing · pending

Vial counts assume the standard 1 - 2 - 4 - 6 - 9 - 12 mg climb on a 10 mg or 24 mg vial size.

Processing

Processed into 32 searchable sections.